EAN 2022 | The ELEGANCE study: levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease

K. Ray-Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, details ELEGANCE (NCT05043103), an observational study assessing levodopa-entacapone-carbidopa intestinal gel for the treatment of advanced Parkinson’s disease (PD). ELEGANCE is currently being set up and the primary endpoints will be to determine the changes in motor function (changes in OFF time and motor experiences of daily living), as well as usage of other anti-parkinsonian medications, changes in global impression of improvement, and long-term safety. Non-motor function, sleep, quality of life, healthcare burden, and costs at centers using this treatment will also be investigated as secondary outcome measures. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.